Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QR-313 in DDEB or RDEB with Exon 73 Mutations
NCT03605069Phase 2Terminated
- Sponsor
- Phoenicis Therapeutics
- Start
- Jul 2018
- Primary completion
- Dec 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 3
01
Overview
A Phase 2 trial of QR-313 in dystrophic epidermolysis bullosa (DEB), sponsored by Phoenicis Therapeutics. Started Jul 2018; status: terminated.
02
Drugs
QR-313
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on NCT03605069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605069.